Triple treatment of high-risk prostate cancer. A matched cohort study with up to 19 years follow-up comparing survival outcomes after triple treatment and treatment with hormones and radiotherapy.
CONCLUSION: Adding surgery in a multimodal treatment model in high-risk prostate cancer showed significantly better survival outcome compared with the current standard of radiotherapy. Surgery in this group is, therefore, compelling and that also includes a clinical T3-stage of the disease. The study is limited by possible selection bias for the two treatment models.
PMID: 30990112 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Endocrine Therapy | External Beam Therapy | Hormones | Neoadjuvant Therapy | PET Scan | Prostate Cancer | Prostatectomy | Study | Urology & Nephrology